[The role of the delta sleep-inducing peptide in the formation of neuropathological syndromes].
Shandra. A A AA; Godlevskiĭ. L S LS; Vast'ianov. R S RS; Brusentsov. A I AI; Moalla. I I; Nikel'. B B
Key Findings
- Central (brain) administration of DSIP caused Parkinsonian and rotational syndromes in experimental models.
- DSIP was linked to the development of epileptic, withdrawal, and other neuropathological syndromes.
- The authors propose DSIP plays a significant role in the mechanisms that lead to these brain disorders.
Practical Outcomes
- For self‑experimenters, the main takeaway is caution: using DSIP, especially via routes that affect the central nervous system, may carry risks of serious neurological side effects. Until more safety data are available, it is advisable to avoid high‑dose or injectable DSIP protocols and to monitor any cognitive or motor changes closely if experimenting with the peptide.
Summary
The study suggests that giving delta‑sleep‑inducing peptide (DSIP) directly into the brain can trigger or worsen several brain disorders, including Parkinson‑like symptoms, seizures, and drug‑withdrawal‑type reactions.
Abstract
The authors considered the pathogenetic role of delta-sleep inducing peptide (DSIP) in different neuropathological syndromes development and manifestation. According to own as well as published in the literature data authors showed the parkinsonian and the rotational syndromes development following DSIP central administration. Briefly, DSIP is a neuropeptide which play significant role in the mechanisms of development of different neuropathological syndromes, namely, epileptic, parkinsonian, withdrawal, rotational and others syndromes.
Study Information
pubmed
1995